Single-chain coronavirus viral membrane protein complexes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current coronavirus vaccines, particularly those based on the S-protein, may not be as immunogenic as the whole viral membrane and are susceptible to protein mutation, necessitating the development of more effective vaccines with longer antibody production duration and stronger resistance to single protein mutations.
Innovation Solution
Development of recombinant coronavirus single-chain (SC) viral membrane protein complexes comprising spike (S), envelope (E), and membrane (M) proteins, designed to mimic total antigenic sites, utilizing linker sequences and expression vectors for production and potential incorporation into nanoparticles for enhanced immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If a single S-protein-based vaccine is used, then the vaccine design is simple and production is easier, but the immunogenicity is reduced and resistance to mutation is weaker
Solution Approach 1:
The patent combines multiple viral membrane proteins (S, E, and M proteins) into a single chimeric protein construct. This merging approach creates a multi-component vaccine antigen that simultaneously presents multiple viral targets to the immune system, thereby enhancing immunogenicity and broadening protection against viral mutations while maintaining a unified vaccine formulation for simplified production.
2Device complexity
If a single S-protein vaccine is used, then the vaccine formulation is simpler, but the antibody production duration is shorter and protection is less comprehensive
Solution Approach 1:
The chimeric vaccine construct is designed to perform multiple functions simultaneously: it presents multiple viral protein epitopes (S, E, and M proteins) to elicit broader immune responses, extends antibody production duration through sustained immune stimulation, and provides comprehensive protection against different viral strains and mutations. This multi-functional design is achieved within a single unified vaccine formulation.
Data Source
AI summary
Recombinant protein coronavirus antigens and vaccine compositions using the same, include a recombinant protein that is a single-chain (SC) viral membrane protein complex derived from the spike (S), envelop (E) and membrane (M) protein of a coronaviruses such as SARS-CoV-2, the causal agent for COVID-19. Methods for immunization of a subject using the vaccine compositions treats or prevents clinical signs caused by coronaviruses infection.